AIDS Alert Archives – April 1, 2010
April 1, 2010
View Archives Issues
-
New DHHS treatment guidelines green light earlier HIV treatment
HIV clinicians now are advised to consider HIV antiretroviral treatment for patients who have CD4 counts greater than 350 cells/mm3 and perhaps even upon diagnosis. -
Hospital admits, ER visits decline in HIV-infected
A new study shows a continued decline in hospitalizations and emergency department visits among HIV-infected adults in the United States. -
Med adherence leads to health care cost savings
HIV patients in international settings where cheaper drugs are available and who are more adherent to their antiretroviral treatment cost less overall to treat than do patients who are less adherent, a new study shows. -
HIV rate 44 times higher in gay, bisexual men
A new data analysis by the Centers for Disease Control and Prevention underscores the disproportionate impact of HIV and syphilis among gay and bisexual men in the United States. -
Abstract & Commentary: Acyclovir for Prevention of HIV Transmission
In a study of HIV transmission, 3,408 HIV-1 serodis cordant couples were enrolled at 14 sites in Africa. -
HIV patients have six-fold higher rates of CA-MRSA
The HIV epidemic has converged with emerging community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), a complication that raises both new challenges and opens possible avenues to prevention, researchers report. -
FDA Notifications
On Feb. 12, 2010, the Food and Drug Administration (FDA) granted tentative approval for efavirenz cross-scored tablets, 200 mg, manufactured by Strides Arcolab Limited of Bangalore, India. The cross-scored tablet can be broken into two 100 mg or four 50 mg doses to facilitate pediatric dosing.